B Cell Dysregulation in Immune Mediated Diseases
Author | : Kartik Bhamidipati |
Publisher | : |
Total Pages | : |
Release | : 2021 |
ISBN-10 | : OCLC:1262571426 |
ISBN-13 | : |
Rating | : 4/5 ( Downloads) |
Download or read book B Cell Dysregulation in Immune Mediated Diseases written by Kartik Bhamidipati and published by . This book was released on 2021 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Alterations in B cell homeostasis drive pathogenesis of various immune mediated diseases. Breaks in peripheral tolerance allow autoreactive B cells to differentiate in to pathogenic auto-antibody secreting cells. B cells themselves may directly drive pathogenesis through antigen-presentation capabilities and secretion of pro-fibrotic factors. Lastly, the inability of B cells to mount effective responses against pathogens may trigger subsequent inflammatory or autoimmune reactions. In this work, we dissect various ways in which B cells contribute to pathogenesis of inflammatory disease by evaluating their role in three different immune mediated diseases. In chapter 2 we identify a potential regulatory role for B cells in the context of Systemic Lupus Erythematosus (SLE), an autoimmune disease characterized by the pathogenic secretion of anti-nuclear antibodies. We found that CD52 is a B cell regulatory glycoprotein elevated on the surface of B cells in patients and acts to suppress B cell hyperactivity both through its surface expression and through the secretion of a soluble form that can bind receptor Siglec-10. In chapter 3 we describe a population of B cells that is significantly expanded in IgG4-RD, a fibroinflammatory condition characterized by infiltration of IgG4+ plasma cells into tumefactive lesions and the development of storiform fibrosis. The expanded population of B cells was CD21-- and CXCR5+, expressing high levels of pathogenic B cell marker CD11c. Moreover, the frequency of this expanded population correlated with clinical parameters such as IgG4 titers. We observed a tremendous elevation of CXCL13, the ligand for CXCR5, strongly implicating the CXCR5-CXCL13 axis in recruiting B cells to affected tissue, making it a viable therapeutic target. Lastly, in chapter 4 we performed high-dimensional sequencing on B cells from sarcoidosis patients, a disease characterized by spontaneous granuloma formation. Although B cells have not been directly implicated in the inflammation, we observed a less diverse and less mutated B cell receptor repertoire; together, our findings point to the initiation of sarcoidosis after ineffective antibody mediated clearance of pathogen from affected organs. In total, this work sheds novel insights on the role of B cells-- from the initial stages of activation and germinal center recruitment, to the development of a diverse antibody repertoire-- in the context of poorly understood immune mediated conditions and contributes important knowledge for the advancement of better treatments for affected patients.